C15:0 (Pentadecanoic Acid): The Odd-Chain Fatty Acid Rewriting Longevity Science (2026)

For decades, nutrition science operated under a simple rule: saturated fats are bad, unsaturated fats are good. Omega-3s were the hero. Everything else was background noise.

Then a Navy epidemiologist named Stephanie Venn-Watson started asking why dolphins in managed care – eating controlled diets – were developing the same age-related diseases as humans: diabetes, fatty liver, chronic inflammation. The culprit wasn't what they were eating too much of. It was what they weren't getting enough of.

The answer was C15:0 – pentadecanoic acid – an odd-chain saturated fatty acid found in trace amounts in whole-fat dairy, certain fish, and some plants. Not omega-3. Not omega-6. A completely different class of fatty acid that the scientific community had largely ignored.

What followed was a cascade of research linking low C15:0 levels to virtually every major age-related disease. And a body of mechanistic evidence showing that C15:0 operates through longevity pathways – AMPK (an energy-sensing enzyme that activates when cellular energy is low – triggers repair processes) activation, PPAR receptor agonism, and mitochondrial membrane stabilization – that overlap remarkably with the mechanisms targeted by the most studied longevity compounds.

This guide covers the science: what C15:0 is, why levels decline with age, what the epidemiological and mechanistic evidence shows, how it differs from omega-3s, and whether supplementation is worth considering.

TL;DR

• C15:0 (pentadecanoic acid) is an odd-chain saturated fatty acid now proposed as an essential nutrient – the first new essential fatty acid identified in 90 years
• Population studies consistently link low C15:0 blood levels to higher rates of type 2 diabetes, cardiovascular disease, fatty liver disease (NAFLD), and all-cause mortality
• C15:0 works through multiple longevity-relevant mechanisms: AMPK activation, PPARα/δ agonism, mitochondrial membrane stabilization, and anti-inflammatory effects
• Dietary C15:0 intake has declined ~50% since the 1970s due to the shift from whole-fat to low-fat dairy
• Food sources include whole-fat dairy (butter, full-fat milk, cheese) and certain fish – but concentrations are low
• Supplemental C15:0 (pure free fatty acid form) is available at doses of 100mg/day
• C15:0 addresses different mechanisms than omega-3s – they are complementary, not redundant

What Is C15:0?

C15:0, or pentadecanoic acid, is a 15-carbon saturated fatty acid with an odd number of carbons. Most fatty acids in the human diet have even-numbered carbon chains (C16:0 palmitic acid, C18:0 stearic acid, C18:1 oleic acid). Odd-chain fatty acids are unusual – and for decades, they were considered biologically unimportant.

That assumption was wrong.

C15:0 is classified as a saturated fat, but it behaves nothing like the long-chain saturated fats (palmitic acid, stearic acid) that earned saturated fat its bad reputation. C15:0 is shorter (15 carbons vs. 16-18), metabolically distinct, and operates through entirely different cellular pathways.

Why It's Called "Essential"

In 2020, Venn-Watson et al. published a peer-reviewed paper in Scientific Reports (Nature Publishing Group) arguing that C15:0 meets all three criteria for essential fatty acid classification:

1. It's not adequately synthesized by the body. While trace amounts of odd-chain fatty acids can be produced endogenously through alpha-oxidation of even-chain fats, this process is inefficient and doesn't maintain adequate tissue levels.

2. Deficiency is associated with disease. Population-level data consistently shows that lower C15:0 blood levels predict higher rates of metabolic disease, cardiovascular disease, and mortality.

3. Supplementation reverses deficiency-related dysfunction. Cell-based and animal studies show that adding C15:0 back to deficient systems restores normal cellular function.

If the essential fatty acid designation holds up to further scrutiny, C15:0 would be the first new essential fatty acid identified since omega-3 (alpha-linolenic acid) and omega-6 (linoleic acid) were classified in the 1930s.

The Epidemiological Evidence

The population-level data linking C15:0 to health outcomes is remarkably consistent across studies, geographies, and populations.

Cardiovascular Disease

A 2012 prospective study in PLOS Medicine by Khaw et al. (the EPIC-Norfolk study) examined the association between plasma phospholipid fatty acid levels and incident coronary heart disease in men and women. C15:0 blood levels were inversely associated with coronary heart disease risk – higher C15:0 levels correlated with lower cardiovascular risk.

A subsequent analysis from the EPIC-InterAct study (N=27,000+) confirmed the finding: individuals in the highest quintile of blood C15:0 had significantly lower risk of type 2 diabetes and cardiovascular events compared to those in the lowest quintile.

Type 2 Diabetes

The diabetes association is particularly strong. Forouhi et al. (2014, The Lancet Diabetes & Endocrinology) analyzed data from the EPIC-InterAct cohort (12,403 incident diabetes cases, 16,154 controls) and found that higher levels of C15:0 (and the related C17:0, heptadecanoic acid) were associated with significantly lower type 2 diabetes incidence.

The effect sizes were not trivial. In some analyses, doubling C15:0 blood levels was associated with a 25-35% reduction in diabetes risk.

Non-Alcoholic Fatty Liver Disease (NAFLD)

Multiple studies have linked low C15:0 to increased risk of fatty liver. Mechanistically, C15:0 activates PPARα – a nuclear receptor that promotes fatty acid oxidation in the liver. When PPARα activity is low (as occurs with C15:0 deficiency), the liver accumulates fat rather than burning it.

All-Cause Mortality

A 2021 analysis from the UK Biobank (N=113,000+) found that higher odd-chain fatty acid levels (C15:0 and C17:0) were independently associated with lower all-cause mortality over 9 years of follow-up.

The Consistency Problem (for Skeptics)

Observational studies can never prove causation. People with higher C15:0 blood levels might be healthier for reasons unrelated to C15:0 itself – perhaps they eat more whole-fat dairy, which provides other nutrients, or they simply have healthier overall diets.

This is a legitimate concern, and it's why the mechanistic evidence (below) matters. If C15:0 had no plausible cellular mechanism, the epidemiological associations would be less convincing. But C15:0 has multiple well-characterized mechanisms that independently explain the disease associations.

Key Takeaway: Population-level data consistently links higher C15:0 blood levels to lower rates of diabetes, cardiovascular disease, fatty liver, and all-cause mortality — across multiple large cohorts including the EPIC-InterAct study (27,000+) and UK Biobank (113,000+). While observational data cannot prove causation, the consistency across studies, geographies, and endpoints is striking.

How C15:0 Works: The Cellular Mechanisms

1. Cell Membrane Stabilization

Cell membranes are composed of a lipid bilayer. The mechanical properties of this bilayer – its fluidity, rigidity, and permeability – depend on its fatty acid composition.

C15:0 incorporates into cell membranes and increases membrane integrity. Because it's a saturated fat with an odd number of carbons, it packs into the bilayer differently than even-chain saturated fats, providing structural support without the excessive rigidity caused by longer-chain saturated fats.

Venn-Watson et al. (2020, Scientific Reports) demonstrated that C15:0 supplementation improved red blood cell membrane stability in a dose-dependent manner. Fragile cell membranes – a hallmark of aging – became more resilient.

This matters because membrane integrity declines with age across all cell types. Weakened membranes lead to increased cellular fragility, impaired receptor signaling, and reduced cellular resilience to stress.

2. Mitochondrial Function Rescue

C15:0 has been shown to rescue mitochondrial function in cellular models of aging and metabolic dysfunction. The proposed mechanisms include:

• Integration into mitochondrial membranes: The inner mitochondrial membrane, where the electron transport chain (the series of proteins in mitochondria that generate ATP from food) operates, is highly sensitive to lipid composition. C15:0 incorporation may optimize membrane fluidity for electron transport chain function.
• Reduction of mitochondrial ROS: Cells treated with C15:0 show reduced mitochondrial ROS (reactive oxygen species – unstable molecules that damage cells when levels are too high) production, suggesting improved electron transport chain efficiency (fewer electron "leaks").
• Protection against mitochondrial fragmentation: C15:0 treatment reduced pathological mitochondrial fission in stressed cell models.

3. AMPK Activation

C15:0 activates AMPK (AMP-activated protein kinase) – the same master metabolic switch targeted by metformin, berberine, exercise, and caloric restriction. AMPK activation:

• Promotes glucose uptake (explaining the diabetes protection)
• Enhances fatty acid oxidation (explaining the NAFLD protection)
• Inhibits mTOR (a growth-signaling pathway – when overactive, it accelerates aging; when inhibited, it promotes longevity), promoting autophagy (your cells' self-cleaning process – recycling damaged components into usable parts) and cellular maintenance
• Activates SIRT1 (the most-studied sirtuin – regulates DNA repair, metabolism, and stress response), linking to NAD+ (nicotinamide adenine dinucleotide – a coenzyme required for cellular energy and DNA repair)-dependent longevity pathways

The AMPK activation by C15:0 places it squarely in the category of caloric restriction mimetics – compounds that reproduce some of the metabolic benefits of caloric restriction without reducing food intake.

4. PPARα and PPARδ Agonism

C15:0 acts as an agonist (activator) of PPARα and PPARδ nuclear receptors. These receptors regulate:

• PPARα: Fatty acid oxidation, ketogenesis, and anti-inflammatory responses in the liver. PPARα agonism is the mechanism of fibrate drugs used to treat high triglycerides.
• PPARδ: Fatty acid oxidation in skeletal muscle, metabolic flexibility, and exercise-like metabolic effects. PPARδ agonism is one of the most sought-after targets in metabolic drug development.

5. Anti-Inflammatory Effects

C15:0 reduces pro-inflammatory signaling through multiple pathways:

• Decreased IL-6, MCP-1, and other inflammatory cytokines in cell culture models
• Reduced NF-κB activation
• Lower endocannabinoid tone (addressing the overactivated endocannabinoid system associated with metabolic syndrome)

These anti-inflammatory effects are mechanistically relevant because chronic low-grade inflammation ("inflammaging") is one of the central drivers of aging. Reducing it preserves NAD+ levels (by reducing CD38 upregulation), slows telomere attrition, and reduces the inflammatory SASP (senescence-associated secretory phenotype – the cocktail of inflammatory signals senescent cells release) produced by senescent cells (damaged cells that stop dividing but refuse to die – they secrete inflammatory signals that damage surrounding tissue).

Key Takeaway: C15:0 works through five distinct longevity-relevant mechanisms: membrane stabilization, mitochondrial rescue, AMPK activation, PPAR agonism, and anti-inflammatory effects. This makes it a caloric restriction mimetic that also addresses membrane integrity — a combination no other single compound provides. At 100mg/day, the dose is tiny compared to most supplements.

Why C15:0 Levels Are Falling

Here's the uncomfortable public health story: population C15:0 levels have been declining for decades, and the decline correlates with dietary guidelines that may have inadvertently caused harm.

The Low-Fat Dairy Shift

Starting in the 1970s, public health guidelines urged Americans to switch from whole-fat to low-fat dairy to reduce saturated fat intake. The reasoning was based on the (now heavily nuanced) association between total saturated fat intake and cardiovascular disease.

Whole-fat dairy is the primary dietary source of C15:0 for most Western populations. When people switched to skim milk, low-fat yogurt, and reduced-fat cheese, their C15:0 intake dropped.

Estimated decline: Average C15:0 intake in the United States has fallen approximately 50% since the 1970s, according to NHANES dietary analysis data. Blood levels of C15:0 have declined in parallel.

During this same period, rates of type 2 diabetes, obesity, NAFLD, and metabolic syndrome increased dramatically. Correlation isn't causation – many other dietary and lifestyle factors changed simultaneously – but the temporal coincidence is notable.

Age-Related Decline

Beyond dietary shifts, C15:0 blood levels decline with age even in populations with stable dairy intake. This likely reflects:

• Reduced intestinal fat absorption efficiency
• Changes in lipid metabolism and membrane turnover
• Altered gut microbiome composition (some gut bacteria produce odd-chain fatty acids)

Watch: Peter Attia and Andrew Huberman discuss supplement evidence and longevity compound strategies:

C15:0 vs. Omega-3s

C15:0 and omega-3 fatty acids (EPA, DHA) are fundamentally different molecules that target different biological systems. They are complementary, not competitive.

Key differences:

• Omega-3s are primarily anti-inflammatory through SPMs (specialized pro-resolving mediators – molecules that actively turn off inflammation). C15:0 is anti-inflammatory through different mechanisms (NF-κB, cytokine production).
• C15:0 activates AMPK. Omega-3s have minimal AMPK effects.
• C15:0 stabilizes cell membranes. Omega-3s increase membrane fluidity. These are opposite but complementary effects – you need both structural integrity and appropriate fluidity.
• C15:0 is shelf-stable. Omega-3s oxidize readily and require careful handling. Rancid fish oil (oxidized omega-3s) may be pro-inflammatory rather than anti-inflammatory.

The bottom line: if you're taking omega-3s, C15:0 doesn't replace them. It addresses different mechanisms. Think of omega-3s as addressing the "inflammatory resolution" axis and C15:0 as addressing the "metabolic signaling and membrane integrity" axis.

Key Takeaway: C15:0 and omega-3s are complementary, not redundant. Omega-3s resolve inflammation through SPM pathways and increase membrane fluidity; C15:0 activates AMPK, stabilizes membranes, and activates PPAR receptors. If you are already taking omega-3s, C15:0 at 100mg/day addresses mechanisms that omega-3s do not touch.

Supplementation

Available Forms

C15:0 is available as a pure, free fatty acid supplement. The synthetic form is identical to the naturally occurring molecule – a 15-carbon saturated fatty acid chain.

Dosing

The research dosing in cellular and animal studies translates to approximately 100mg/day for humans. This is the dose used in cell-based studies showing AMPK activation, PPARα/δ agonism, and membrane stabilization.

For context, getting 100mg of C15:0 from food would require:

• ~4 cups of whole milk, or
• ~6 ounces of full-fat butter, or
• ~3 cups of full-fat yogurt

Supplementation provides a more practical way to achieve consistent daily intake.

Safety

Safety Note: While C15:0 has GRAS status and no reported adverse effects, long-term human supplementation studies are limited. If you take blood-thinning medications or have a bleeding disorder, consult your physician before adding any new fatty acid supplement.

C15:0 is a naturally occurring fatty acid found in common foods. No adverse effects have been reported in published research at supplemental doses. It's a GRAS (Generally Recognized as Safe) food component. However, long-term supplementation studies in humans are limited, and the compound is relatively new to the supplement market.

What to Look For

• Pure C15:0 (FA15): Look for supplements providing pure pentadecanoic acid, not just dairy fat concentrates.
• Free fatty acid form: Better absorption than triglyceride-bound forms.
• Third-party tested: Standard quality assurance for purity and contaminant absence.
• Vegan availability: Synthetic C15:0 is vegan. Dairy-derived forms are not.

Full episode: Rhonda Patrick and Andrew Huberman on micronutrients, fatty acids, and cellular health:

How C15:0 Fits Into a Longevity Protocol

C15:0 addresses several aging hallmarks through its multi-target mechanism profile:

• Mitochondrial dysfunction: Membrane stabilization + ROS reduction
• Deregulated nutrient sensing: AMPK activation
• Chronic inflammation: NF-κB inhibition, cytokine reduction
• Loss of proteostasis: AMPK-mediated autophagy promotion

In a structured longevity protocol:

NAD+ restoration (NMN, nicotinamide mononucleotide – the direct precursor your body converts into NAD+, 600mg/day) addresses the coenzyme decline that impairs DNA repair, sirtuin function, and energy metabolism.

Cellular membrane integrity (C15:0 100mg/day) addresses the structural deterioration that makes cells more fragile and less responsive to signaling.

Mitochondrial quality control (CoQ10/Ubiquinol, coenzyme Q10 – an antioxidant that powers mitochondrial energy production, 100mg + PQQ, pyrroloquinoline quinone – a compound that stimulates new mitochondria growth, 20mg) addresses the energy production and mitochondrial biogenesis (the process of growing new mitochondria) requirements.

Anti-inflammatory and metabolic support (C15:0 + omega-3s) addresses the inflammatory signaling and metabolic dysregulation that accelerate all other aging processes.

The Bottom Line

C15:0 is a genuinely novel finding in longevity nutrition. An odd-chain saturated fatty acid that activates AMPK, agonizes PPARα/δ, stabilizes cell membranes, and reduces inflammation – all at a dose of 100mg/day.

The epidemiological data is consistent and large-scale: lower C15:0 blood levels predict higher rates of diabetes, cardiovascular disease, liver disease, and all-cause mortality. The mechanistic data provides plausible explanations for these associations.

The main caveat: randomized controlled trials in humans are still limited. The evidence base is strong at the epidemiological and mechanistic levels but hasn't yet been confirmed by large-scale human intervention trials. The science is promising, the safety profile is clean, and the cost of supplementation is low – but this is an earlier-stage longevity compound compared to, say, NMN or CoQ10 with their multiple published RCTs (randomized controlled trials – the gold standard of clinical evidence).

For anyone interested in comprehensive longevity supplementation, C15:0 is worth watching – and potentially worth adding – as a low-risk, mechanistically sound compound targeting aging pathways that other common supplements don't address.

References:

1. Venn-Watson S, et al. (2020). Efficacy of dietary odd-chain saturated fatty acid pentadecanoic acid parallels broad associated health benefits in humans. Scientific Reports, 10, 14753.
2. Forouhi NG, et al. (2014). Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes. The Lancet Diabetes & Endocrinology, 2(10), 810-818.
3. Khaw KT, et al. (2012). Plasma phospholipid fatty acid concentration and incident coronary heart disease in men and women: the EPIC-Norfolk prospective study. PLOS Medicine, 9(7), e1001255.
4. Venn-Watson S, et al. (2022). C15:0 (pentadecanoic acid) as a cell-based and clinically relevant biomarker. PLOS ONE, 17(5), e0268778.
5. Huang L, et al. (2021). Circulating saturated fatty acids and incident type 2 diabetes: a systematic review and meta-analysis. Nutrients, 13(9), 3191.
6. Yi L, et al. (2023). The efficacy and safety of NMN supplementation. GeroScience, 45(1), 29-43.

Frequently Asked Questions

Q: What is C15:0 and why does it matter for longevity?

C15:0 (pentadecanoic acid) is an odd-chain saturated fatty acid proposed as the first new essential fatty acid in 90 years. It activates AMPK (the same pathway as caloric restriction and metformin), agonizes PPARα/δ receptors, stabilizes cell membranes, and reduces inflammation. Lower blood levels of C15:0 are consistently associated with higher rates of type 2 diabetes, cardiovascular disease, fatty liver, and all-cause mortality in large population studies.

Q: How is C15:0 different from omega-3 fatty acids?

C15:0 is a short, odd-chain saturated fat. Omega-3s (EPA, DHA) are long-chain polyunsaturated fats. They work through completely different mechanisms: C15:0 activates AMPK and stabilizes cell membranes, while omega-3s reduce inflammation through specialized pro-resolving mediators and increase membrane fluidity. They are complementary supplements targeting different aspects of cellular health.

Q: What foods contain C15:0?

Whole-fat dairy products are the richest dietary source: full-fat milk, butter, cream, and cheese. Some fish also contain C15:0. However, dietary concentrations are low – you'd need approximately 4 cups of whole milk daily to reach the supplemental dose of 100mg. The shift from whole-fat to low-fat dairy since the 1970s has reduced average C15:0 intake by approximately 50%.

Q: Is C15:0 safe to take as a supplement?

C15:0 is a naturally occurring fatty acid found in common foods consumed by humans for thousands of years. No adverse effects have been reported at supplemental doses of 100mg/day. It has GRAS status. However, long-term human supplementation studies are limited compared to more established longevity supplements, as C15:0 is relatively new to the supplement market.

Q: Can I take C15:0 with NMN?

Yes. C15:0 and NMN target different aging mechanisms and operate through non-overlapping pathways. NMN restores NAD+ levels for sirtuin function and DNA repair. C15:0 activates AMPK, stabilizes cell membranes, and reduces inflammation. The combination addresses a broader range of aging hallmarks than either compound alone. No adverse interactions have been reported.

Related Reading

• Omega-3 and Longevity: Beyond Heart Health
• The Mitochondrial Theory of Aging: Why Your Cellular Power Plants Matter
• Inflammaging: The Chronic Inflammation That Drives Every Aging Hallmark
• Longevity Blood Tests: What to Track and Why Your Doctor Doesn't Order Them
• The 12 Hallmarks of Aging: Why You Age and What Targets Each One
• CoQ10 Ubiquinol: The Mitochondrial Fuel Your Body Stops Making After 40

Daily Compounds – your habits are dialed. Your cells aren’t. Learn more →